Nuvation Bio Completes Acquisition of AnHeart Therapeutics
Nuvation Bio to Acquire AnHeart Therapeutics in All-Stock Transaction
Innovent and AnHeart Announce the NMPA Has Accepted NDA for Taletrectinib
AnHeart and Innovent Announce NMPA has Accepted Second NDA for Taletrectinib
AnHeart and Innovent Announce NMPA Has Granted Taletrectinib Priority Review
AnHeart Therapeutics and Foundation Medicine Announce Collaboration
AnHeart Therapeutics Expands U.S. Leadership With Development and Commercial Leads
AnHeart Therapeutics Announces Exclusive License Agreement With Nippon Kayaku for Taletrectinib in Japan
NEW YORK--(BUSINESS WIRE)--AnHeart Therapeutics (“AnHeart”), a global clinical-stage biopharmaceutical company developing novel precision therapies for people with cancer, today announced positive interim results from its global pivotal Phase 2 clinical trial, TRUST-II. Interim data from the trial showed taletrectinib, AnHeart’s investigational next-generation ROS1 inhibitor, shrank tumors (confirmed objective response rate, cORR, as assessed by an independent review committee, IRC) in 92% of patients with advanced ROS1-positive non-small cell lung cancer (NSCLC) who had not previously been treated with a ROS1 tyrosine kinase inhibitor (TKI naïve). Taletrectinib shrank tumors in 57% of patients who had previously been treated with a ROS1 TKI (TKI pre-treated). Taletrectinib also showed robust intracranial activity in the subgroup of patients with disease that had spread to the brain.
AnHeart Therapeutics Appoints Charlotte Arnold as Chief Corporate Affairs Officer